(Q39182945)

9 September 2017

title

Strategies and challenges for the next generation of antibody-drug conjugates (English)

1 reference

9 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Alain Beck

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Liliane Goetsch

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Nathalie Corvaïa

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

17 March 2017

1 reference

Nature Reviews Drug Discovery

9 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

315-337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

Antibody-drug conjugates: current status and future directions

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates: present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The cryptophycins as potent payloads for antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Microtubule-binding agents: a dynamic field of cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates: an emerging concept in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

TP53 loss creates therapeutic vulnerability in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Cell killing by antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Brentuximab Vedotin (SGN-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Strategies and challenges for the next generation of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Characterization of therapeutic antibodies and related products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The INNs and outs of antibody nonproprietary names

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Rethinking the INN system for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Marketing approval of mogamulizumab: a triumph for glyco-engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Design and application of antibody cysteine variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Improving the serum stability of site-specific antibody conjugates with sulfone linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Methods to Make Homogenous Antibody Drug Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A general approach to site-specific antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The covalent structure of an entire gammaG immunoglobulin molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-specific antibody-drug conjugation through glycoengineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Covalent Chemical Ligation Strategy for Mono- and Polyclonal Immunoglobulins at Their Nucleotide Binding Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Long-term stabilization of maleimide-thiol conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-targeted drugs and drug resistance--challenges and solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Mechanisms of Resistance to Antibody-Drug Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Emerging formats for next-generation antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates for non-oncological indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

An immunosuppressive antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I - Optimization of separation conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. II- Identification of sub-units for the char

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Characterization of cetuximab Fc/2 dimers by off-line CZE-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Why is it so difficult to use gemtuzumab ozogamicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Effect of attachment site on stability of cleavable antibody drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Computational selection of antibody-drug conjugate targets for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Therapeutic antibodies and derivatives: from the bench to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

2015 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Prognostic value of S-phase cells in AML patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

Investigation of Optical Coherence Microelastography as a Method to Visualize Cancers in Human Breast Tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin

31 March 2020

1 reference

12 December 2020

Monoclonal antibodies in myeloma.

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

1 reference

12 December 2020

Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms

1 reference

12 December 2020

The next generation of antibody-drug conjugates comes of age.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 June 2020

1084129613

0 references

Fatcat ID

release_lo6kvg7k4fgfvodd4sww2a2dqy

0 references

1 reference